Regulus Therapeutics Inc. (NASDAQ:RGLS) Sees Significant Decline in Short Interest

Regulus Therapeutics Inc. (NASDAQ:RGLS) was the target of a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 1,690,000 shares, a decline of 32.4% from the October 15th total of 2,500,000 shares. Based on an average trading volume of 359,700 shares, the days-to-cover ratio is presently 4.7 days. Currently, 3.2% of the shares of the company are sold short.

Hedge Funds Weigh In On Regulus Therapeutics

A number of institutional investors have recently made changes to their positions in RGLS. Creative Planning bought a new stake in shares of Regulus Therapeutics during the 3rd quarter worth $26,000. SG Americas Securities LLC bought a new stake in Regulus Therapeutics during the third quarter worth about $33,000. Jane Street Group LLC bought a new stake in Regulus Therapeutics during the third quarter worth about $46,000. Barclays PLC boosted its holdings in shares of Regulus Therapeutics by 285.2% in the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 62,549 shares in the last quarter. Finally, Rhumbline Advisers bought a new position in shares of Regulus Therapeutics during the 2nd quarter valued at about $136,000. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Stock Down 4.7 %

NASDAQ:RGLS traded down $0.07 during trading hours on Friday, hitting $1.43. 261,914 shares of the company’s stock traded hands, compared to its average volume of 1,249,951. Regulus Therapeutics has a 52 week low of $1.08 and a 52 week high of $3.79. The business’s fifty day simple moving average is $1.55 and its two-hundred day simple moving average is $1.80. The firm has a market cap of $93.67 million, a P/E ratio of -1.34 and a beta of 1.63.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). On average, analysts expect that Regulus Therapeutics will post -0.88 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on RGLS shares. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a report on Monday, November 11th. StockNews.com raised Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. Finally, Oppenheimer reissued an “outperform” rating and issued a $7.00 price target on shares of Regulus Therapeutics in a report on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.